PBAC's latest decision on Ustekinumab: Recommended (2025). Considered for Severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe ulcerative colitis.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
12
first 2014
PBS spend
$436M
60,131 scripts · 2024
Eligible population
Adults and paediatric patients with severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe ulcerative colitis, as per the same circumstances as the PBS-listed reference biologic Stelara.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Other
Comparator
Stelara (ustekinumab reference biologic)
Economic model
Cost-minimisation
ICER note
Cost-minimisation submission; no ICER calculated. Epyztek recommended on cost-minimisation basis to Stelara at effective price.
PBS expenditure
The Australian government paid $436M in PBS benefits for Ustekinumab in 2024 across 60,131 scripts, at $7,242 per script.
Submission history
Nov 2014: Not recommended · Authority Required
Jul 2015: Recommended with restriction · Restricted
Nov 2015: Recommended with restriction · Authority Required
Mar 2017: Recommended with restriction · Authority Required
Mar 2021: Recommended with restriction · Authority Required
Jul 2022: Recommended · Authority Required
Jul 2022: Recommended with restriction · Authority Required
Jul 2023: Not recommended · Restricted
Mar 2024: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required
Nov 2024: Recommended with restriction · Authority Required